IL1B and myocardial infarction: In the CANTOS (Cardiovascular Risk Reduction Study [Reduction in Recurrent Major CV Disease Events]) trial, IL-1 blockade using canakinumab led to fatal infections and did not result in the improvement of all-cause mortality in myocardial infarction patients.33